Edition:
Deutschland

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,171JPY
16 Aug 2018
Change (% chg)

¥-8 (-0.37%)
Prev Close
¥2,179
Open
¥2,180
Day's High
¥2,205
Day's Low
¥2,165
Volume
1,109,900
Avg. Vol
1,283,312
52-wk High
¥2,536
52-wk Low
¥1,416

4506.T

Chart for 4506.T

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Japan segment manufactures and sells ethical and general use drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other... (more)

Buy/Sell

Sell Hold Buy
3.50 Mean rating from 10 analysts

Overall

Beta: 0.76
Market Cap(Mil.): ¥604,410.31
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.18
Photo

Nikkei rises in volatile trade helped by China stock gains

TOKYO Japan's Nikkei share average rose in volatile trade on Wednesday, helped by late short-covering following an earlier selloff and a broader recovery in regional sentiment as Chinese shares recovered from a rout in the previous session.

Nikkei rises in volatile trade helped by China stock gains

TOKYO, June 20 Japan's Nikkei share average rose in volatile trade on Wednesday, helped by late short-covering following an earlier selloff and a broader recovery in regional sentiment as Chinese shares recovered from a rout in the previous session.

Nikkei flat in choppy trade as trade war woes pressures; Kikkoman soars

TOKYO, June 20 Japan's Nikkei share average was flat in choppy trade on Wednesday morning as firms that rely on China demand tumbled on trade war worries, with machine tool makers and shippers posting multi-month lows, which offset gains in defensive stocks.

BRIEF-Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors

* Says it and Sumitomo Dainippon Pharma Co Ltd , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

BRIEF-Sumitomo Dainippon Pharma says change of president

* Says it appoints Masayo Tada as chairman of the board, and Hiroshi Nomura as president, effective April 1

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.51%
Rohstoffe +0.52%
Industrie +0.57%
Konjunktur abhängige Waren & Dienstleistungen +1.05%
Konjunktur unabhängige Waren & Dienstleistungen +0.88%
Finanzindustrie +0.64%
Pharma +0.65%
Technologie +0.74%
Telekommunikation +0.66%